CA997756A - 1,2,4-triazole nucleosides - Google Patents

1,2,4-triazole nucleosides

Info

Publication number
CA997756A
CA997756A CA143,816A CA143816A CA997756A CA 997756 A CA997756 A CA 997756A CA 143816 A CA143816 A CA 143816A CA 997756 A CA997756 A CA 997756A
Authority
CA
Canada
Prior art keywords
triazole nucleosides
nucleosides
triazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA143,816A
Other languages
English (en)
Inventor
Joseph T. Witkowski
Roland K. Robins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch Health Americas Inc
Original Assignee
ICN Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ICN Pharmaceuticals Inc filed Critical ICN Pharmaceuticals Inc
Application granted granted Critical
Publication of CA997756A publication Critical patent/CA997756A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA143,816A 1971-06-01 1972-05-31 1,2,4-triazole nucleosides Expired CA997756A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14901771A 1971-06-01 1971-06-01
US24025272A 1972-03-31 1972-03-31

Publications (1)

Publication Number Publication Date
CA997756A true CA997756A (en) 1976-09-28

Family

ID=26846393

Family Applications (1)

Application Number Title Priority Date Filing Date
CA143,816A Expired CA997756A (en) 1971-06-01 1972-05-31 1,2,4-triazole nucleosides

Country Status (28)

Country Link
US (1) US3798209A (OSRAM)
JP (5) JPS5527076B1 (OSRAM)
AR (1) AR199463A1 (OSRAM)
AU (1) AU461900B2 (OSRAM)
BE (1) BE784195A (OSRAM)
BG (1) BG22827A3 (OSRAM)
CA (1) CA997756A (OSRAM)
CH (1) CH614452A5 (OSRAM)
DD (1) DD99791A5 (OSRAM)
DE (1) DE2220246A1 (OSRAM)
DK (2) DK143069C (OSRAM)
EG (1) EG11406A (OSRAM)
ES (1) ES403142A1 (OSRAM)
FR (1) FR2140126B1 (OSRAM)
GB (1) GB1353565A (OSRAM)
HK (1) HK23876A (OSRAM)
HU (1) HU167614B (OSRAM)
IE (1) IE36478B1 (OSRAM)
IL (1) IL39416A (OSRAM)
IN (1) IN142290B (OSRAM)
IS (1) IS913B6 (OSRAM)
LU (1) LU65446A1 (OSRAM)
MC (1) MC921A1 (OSRAM)
MY (1) MY7600203A (OSRAM)
NL (1) NL7207156A (OSRAM)
NO (1) NO138805C (OSRAM)
RO (1) RO62435A (OSRAM)
SE (3) SE405604B (OSRAM)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
DE2401449A1 (de) * 1973-01-16 1974-07-25 Voorhees Pharmazeutische zusammensetzung zur linderung von hautproliferationserkrankungen
US3888843A (en) * 1973-06-12 1975-06-10 Toyo Jozo Kk 4-carbamoyl-1-' -d-ribofuranosylimidazolium-5-olate
AR207138A1 (es) * 1974-03-18 1976-09-15 Icn Pharmaceuticals Metodo para la obtencion de 1,2,4-triazoles n-substituidos y sus sales de adicion
GB1482736A (en) * 1974-03-18 1977-08-10 Icn Pharmaceuticals 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives
US3960836A (en) * 1974-07-22 1976-06-01 Eli Lilly And Company Acylated derivatives of pyrazofurin and process for their preparation
US4007198A (en) * 1975-05-01 1977-02-08 American Cyanamid Company Substituted 1,2,4-triazole carboxamide
US4138547A (en) * 1977-12-22 1979-02-06 Icn Pharmaceuticals, Inc. Process for preparing 1,2,4-triazole nucleosides
JPS57146593A (en) * 1981-03-09 1982-09-10 Ajinomoto Co Inc Preparation of ribofuranosyltriazole derivative
US4451648A (en) * 1981-08-19 1984-05-29 The United States Of America As Represented By The Department Of Health And Human Services Process for the production of 2-β-D-ribofuranosylthiazole-4-carboxamide
US4531001A (en) * 1982-03-23 1985-07-23 Brigham Young University 2-β-D-ribofuranosylselenazole-4-carboxamide compounds
US4446315A (en) * 1982-09-24 1984-05-01 The United States Of America As Represented By The Department Of Health And Human Services Adenosine 5'-triphosphate-4-carboxamide-ribofuranosylthiazole
JPS5964648U (ja) * 1982-10-22 1984-04-28 阿波野　政晴 日覆用骨格
BE902199A (fr) * 1984-10-29 1985-07-31 Vira Tek Inc Procede de traitement medical de maladies virales utilisant le 1-beta-d-ribofurannosyl-1, 2,4-triazole-3-carboxamide.
NZ213370A (en) * 1985-01-16 1989-03-29 Vira Tek Inc Method of treating viral infections of selected trees and field crops using ribavirin (1-b-d-ribofuranosyl-1,2,4-triazole-3-carboxamide) or the 2,3,5-triacetyl or 5'-butyryl derivative thereof
DE3606634A1 (de) * 1986-02-28 1987-09-03 Mack Chem Pharm Isohexid-nucleoside, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE135914T1 (de) * 1986-03-27 1996-04-15 Gensia Inc Aica riboside zur prophylaktischen behandlung von krankheiten mit einer verminderten durchblutung.
US4925930A (en) * 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
US5438131A (en) * 1992-09-16 1995-08-01 Bergstrom; Donald E. 3-nitropyrrole nucleoside
YU47802A (sh) * 1999-12-23 2006-03-03 Ribapharm Postupci i kompozicije za levovirin
US7638496B2 (en) * 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US6455508B1 (en) * 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
PL359169A1 (en) * 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
US6815542B2 (en) * 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
AU2001220806A1 (en) * 2000-08-22 2002-03-04 Ribapharm Inc. Improved specificity in treatment of diseases
WO2002044717A1 (en) * 2000-12-01 2002-06-06 Cornell Research Foundation Animal model for flaviviridae infection
US20040014696A1 (en) * 2000-12-07 2004-01-22 Johnson Lau Specificity in treatment of diseases
US6720000B2 (en) * 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
DE60101056T2 (de) * 2001-07-30 2004-05-19 Clariant Life Science Molecules (Italia) S.P.A., Origgio Verfahren zur Herstellung von Ribavirin
US7138376B2 (en) * 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
MXPA04004181A (es) * 2001-11-02 2005-01-25 Sandoz Ag Procedimiento para preparar composiciones de ribavirina de alta carga, de rapida disolucion.
KR100411398B1 (ko) 2001-12-06 2003-12-18 주식회사유한양행 베타-디-리보푸라노즈 유도체의 제조방법
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CA2489552A1 (en) * 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
TW200500374A (en) 2002-06-28 2005-01-01 Idenlx Cayman Ltd 2' and 3' -nucleoside produrgs for treating flavivridae infections
US20040067877A1 (en) * 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
US7538094B2 (en) * 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
SI1576138T1 (sl) 2002-11-15 2017-07-31 Idenix Pharmaceuticals Llc 2'-metil nukleozidi v kombinaciji z interferon in flaviviridae mutacijo
ES2470771T3 (es) * 2002-12-12 2014-06-24 Idenix Pharmaceuticals, Inc Procedimiento para la producción de nucle�sidos ramificados en 2'
EP1575971A4 (en) * 2002-12-23 2008-03-05 Idenix Cayman Ltd PROCESS FOR THE PREPARATION OF 3-NUCLEOSIDE PRODRUGS
RU2005133093A (ru) * 2003-03-28 2006-07-27 Фармассет, Инк. (Us) Соединения для лечения флавивирусных инфекций
PT1633766T (pt) 2003-05-30 2019-06-04 Gilead Pharmasset Llc Análogos de nucleósido fluorado modificado
EP1658302B1 (en) * 2003-07-25 2010-08-25 IDENIX Pharmaceuticals, Inc. Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
WO2005018330A1 (en) * 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
US20050187192A1 (en) * 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
EP1912643A2 (en) * 2004-06-23 2008-04-23 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
SI3109244T1 (sl) * 2004-09-14 2019-06-28 Gilead Pharmasset Llc Priprava 2'fluoro-2'-alkil-substituiranih ali drugih neobvezno substituiranih ribofuranozil pirimidinov in purinov in njihovih derivatov
EP2305696A3 (en) * 2005-07-25 2011-10-12 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
JP2009511595A (ja) * 2005-10-11 2009-03-19 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルスの複製を阻害する化合物および方法
WO2007075876A2 (en) * 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
MX2008013119A (es) 2006-04-11 2008-10-21 Novartis Ag Inhibidores de hcv/vih y sus usos.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2201953A4 (en) 2007-08-27 2011-08-03 Univ Nagoya Nat Univ Corp USE OF RIBAVIRIN IN BLOOD CLEANING DISORDERS
JPWO2009028575A1 (ja) 2007-08-27 2010-12-02 国立大学法人名古屋大学 血液凝固第ｖｉｉ因子プロモーターの活性化剤及びその利用
US20090082414A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched viramidine
WO2009105258A1 (en) 2008-02-22 2009-08-27 Nektar Therapeutics Al, Corporation Oligomer conjugates of heteropentacyclic nucleosides
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
EP2282762A2 (en) * 2008-04-15 2011-02-16 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CA2740728A1 (en) * 2008-10-15 2010-04-22 Intermune, Inc. Therapeutic antiviral peptides
MX2011006152A (es) 2008-12-09 2011-07-28 Gilead Sciences Inc Moduladores de receptores tipo toll.
CN102753563A (zh) * 2008-12-23 2012-10-24 吉利德制药有限责任公司 核苷类似物
SG172363A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Synthesis of purine nucleosides
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2011038293A1 (en) * 2009-09-28 2011-03-31 Intermune, Inc. Cyclic peptide inhibitors of hepatitis c virus replication
WO2011041551A1 (en) * 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
WO2011076923A1 (en) 2009-12-23 2011-06-30 Institut National De La Sante Et De La Recherche Medicale Inhibitor for inosine monophosphate (imp) dehydrogenase and/or viral rna polymerase for treatment of hepatitis e
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2528436A4 (en) * 2010-01-25 2013-07-10 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
WO2011123668A2 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Stereoselective synthesis of phosphorus containing actives
JP5909495B2 (ja) 2010-10-08 2016-04-26 ノバルティス アーゲー スルファミドｎｓ３阻害剤のビタミンｅ製剤
EP2646453A1 (en) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Compounds
CA2822037A1 (en) 2010-12-20 2012-06-28 Gilead Sciences, Inc. Methods for treating hcv
CA2752008A1 (en) 2011-09-13 2013-03-13 Universite De Montreal Combination therapy using ribavirin as elf4e inhibitor
SG10201602044WA (en) 2011-09-16 2016-04-28 Gilead Pharmassett Llc Methods For Treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CA2889903C (en) 2012-10-29 2021-03-09 Manjinder Singh Phull Antiviral phosphonate analogues and process for preparation thereof
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
AU2014202687A1 (en) 2013-01-31 2014-08-14 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
SI3038601T1 (sl) 2013-08-27 2020-07-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin
EP2959888A1 (en) 2014-06-23 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. A novel pharmaceutical composition of sofosbuvir and ribavirin
EP2959891A1 (en) 2014-06-23 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. Modified release pharmaceutical compositions of sofosbuvir and ribavirin
EA201692507A1 (ru) 2014-06-23 2017-04-28 Сановель Илач Санайи Ве Тиджарет А.Ш. Фармацевтические комбинации софосбувира и рибавирина
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
EP3194401B1 (en) 2014-09-16 2020-10-21 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
UY37381A (es) 2016-08-30 2018-03-23 Glaxosmithkline Ip No 2 Ltd Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos
CN110713464B (zh) * 2019-10-31 2023-03-31 重庆大学 一种芳基1,2,4-三氮唑核苷化合物及其制备方法和应用
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Also Published As

Publication number Publication date
NO138805C (no) 1978-11-15
SE7801925L (sv) 1978-02-20
BE784195A (fr) 1972-11-30
DK143069B (da) 1981-03-23
HU167614B (OSRAM) 1975-11-28
MC921A1 (fr) 1973-01-25
JPS5519239B2 (OSRAM) 1980-05-24
DE2220246A1 (de) 1972-12-14
IS2075A7 (is) 1973-01-02
IS913B6 (is) 1975-09-15
HK23876A (en) 1976-04-30
JPS5519238B2 (OSRAM) 1980-05-24
AU461900B2 (en) 1975-06-12
SE405604B (sv) 1978-12-18
JPS5527076B1 (OSRAM) 1980-07-17
IL39416A0 (en) 1972-07-26
US3798209A (en) 1974-03-19
BG22827A3 (bg) 1977-04-20
NL7207156A (OSRAM) 1972-12-05
JPS5395974A (en) 1978-08-22
AR199463A1 (es) 1974-09-09
GB1353565A (en) 1974-05-22
RO62435A (fr) 1978-03-15
AU4215772A (en) 1973-12-20
DD99791A5 (OSRAM) 1973-08-20
JPS53124271A (en) 1978-10-30
ES403142A1 (es) 1975-05-01
CH614452A5 (en) 1979-11-30
IE36478B1 (en) 1976-11-10
IL39416A (en) 1975-07-28
IE36478L (en) 1972-12-01
JPS5387356A (en) 1978-08-01
DK509876A (da) 1976-11-12
LU65446A1 (OSRAM) 1972-10-05
FR2140126A1 (OSRAM) 1973-01-12
NO138805B (no) 1978-08-07
DK143069C (da) 1981-11-02
SE7801926L (sv) 1978-02-20
MY7600203A (en) 1976-12-31
IN142290B (OSRAM) 1977-06-18
FR2140126B1 (OSRAM) 1976-04-16
EG11406A (en) 1981-06-30
JPS53108973A (en) 1978-09-22

Similar Documents

Publication Publication Date Title
AU461900B2 (en) 1, 2, 4-triazole nucleosides
AU461487B2 (en) Substituted 1, 2, 4-triazole derivatives
CA988092A (en) 4,5-dihalopyrrole-2-carbonitriles
AU463873B2 (en) 1, 4-bis-ACYLPIPERAZINES
CA997763A (en) 2,4,diamino-5-benzylpyrimidine
AU468410B2 (en) 2, 4-diamino-5-benzyl-pyrimidines
CA966138A (en) 1,1-dialkyl-2-(substituted indazolyl-n1-methyl) hydrazines
AU468447B2 (en) 2, 4-diamino-5-benzyl-pyrimidines
CA990288A (en) "2,6-dichloro-benzaldoxime-0-(s-triazinyl-(6))-ethers"
CA976543A (en) 4,6,8(14)-triene-steroids
CA975378A (en) 5-hydoxymethyl-(1,3-dioxa-2-silacyclohexanes)
AU468307B2 (en) 1, 2-biguanides
ZA723239B (en) 1,2,4-triazole nucleosides
AU459270B2 (en) 3, 2-benzoxazepine derivatives
CA874979A (en) 3,4-dihydroquinazolinones
CA883819A (en) 6,9,21-trihalogenosteroids
CA872219A (en) 16,17-alkylidenediazopregnanes
CA874978A (en) 3,4-dihydroquinazolinones
AU452853B2 (en) 4 ALKOXY-l, 2-METHYLENEDIOXYBENZENES
CA881549A (en) 3,4-dihydro-2h-pyrans
CA860938A (en) 4,5,6-trichloro-2-chlorocarbonyl-pyrimidine
CA871120A (en) 3,4-dihydroquinazolinones
CA882143A (en) 3,4-epoxy-4-methylcyclohexanes
CA871704A (en) 2,6-methano-3-benzazocines
CA865727A (en) 4,5-dehydro-3-oxo-19-hydroxysteroids